CriticalFirst-generation antihistamine with anxiolytic activity×Fourth-generation fluoroquinolone
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Moxifloxacin prolongs the QTc interval on the electrocardiogram in some patients, and the prolongation may increase as its blood concentration rises (moxifloxacin SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish moxifloxacin SmPC does not rule out an additive QT effect with other QT-prolonging drugs. Such an effect may raise the risk of ventricular arrhythmias, including torsade de pointes (AEMPS). The Spanish hydroxyzine SmPC names moxifloxacin among the antibiotics that raise the risk of arrhythmia when given with hydroxyzine (AEMPS). A metabolic interaction of moxifloxacin through cytochrome P450 enzymes is unlikely (moxifloxacin SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular arrhythmias, including torsade de pointes, cause palpitations, dizziness and fainting and can lead to cardiac arrest (moxifloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Women and older people may be more sensitive to QT-prolonging drugs (moxifloxacin SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval and names moxifloxacin (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraindication also comes from the moxifloxacin side. The contraindications section of the Spanish moxifloxacin SmPCs rules out moxifloxacin with other QT-prolonging drugs (moxifloxacin SmPCs, AEMPS). Hydroxyzine's own SmPC links it to QT prolongation. The US moxifloxacin label advises avoiding moxifloxacin in people taking other QT-prolonging drugs (moxifloxacin label, US Food and Drug Administration, FDA). The US hydroxyzine label lists moxifloxacin among the drugs that call for caution (hydroxyzine label, FDA). Moxifloxacin is also contraindicated in QT prolongation, electrolyte disturbances (especially uncorrected low potassium), clinically relevant bradycardia, heart failure with reduced ejection fraction and a history of symptomatic arrhythmias (moxifloxacin SmPCs, AEMPS). Hydroxyzine is contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). QT prolongation may increase with moxifloxacin concentration. Do not exceed the recommended dose, and infuse the 400 mg once-daily intravenous dose over at least 60 minutes (moxifloxacin SmPCs, AEMPS). If signs of arrhythmia appear, stop moxifloxacin and record an electrocardiogram (ECG) (moxifloxacin SmPCs, AEMPS), and stop hydroxyzine as well (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b, version 1, 08/2026, sections 5.6 (QT Prolongation) and 7.5 (Drugs that Prolong QT)
- AEMPS: Ficha técnica: Moxifloxacino (nº registro 74573), sección 4.5 (2026)– AEMPS, CIMA, nº registro 74573, revisión 03/2026, sección 4.5
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.3 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, secciones 4.3, 4.4, 4.5 y 4.8